This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Monoamine oxidase inhibitors (MAOIs) may increase the effects of your antihistamine.
What might happen:
Your blood pressure may drop dangerously low.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together. Your doctor may want to change your medicine. Let your doctor know right away if you have any weakness, dizziness, fainting, or blurred vision.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Zadine (azatadine maleate) Australian prescribing information. Schering-Plough Corporation January, 1992.
2.Ambi 1000/5 (guaifenesin/carbetapentane) US prescribing information. AMBI Pharmaceuticals, Inc. March, 2006.
3.PediaTan (chlorpheniramine tannate) US prescribing information. ProEthic Pharmaceuticals, Inc. June, 2006.
4.Carbinoxamine maleate US prescribing information. Zeris Pharma, L.L.C. February, 2007.
5.Cyproheptadine hydrochloride US prescribing information. Cypress Pharmaceutical, Inc. November, 2006.
6.Kahn DA. Possible toxic interaction between cyproheptadine and phenelzine. Am J Psychiatry 1987 Sep;144(9):1242-3.
7.Zyvox (linezolid) US prescribing information. Pfizer January, 2014.
8.Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 2007 Nov;152(6):946-51.
9.Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000 Jun;56(3):247-50.